

Prajwal Dhakal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3529412/publications.pdf>

Version: 2024-02-01

56
papers

546
citations

777949

13
h-index

759306

22
g-index

57
all docs

57
docs citations

57
times ranked

922
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 319-325.	0.2	2
2	Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?. <i>Future Oncology</i> , 2022, 18, 311-321.	1.1	13
3	Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis. <i>Leukemia and Lymphoma</i> , 2022, 63, 939-945.	0.6	1
4	Impact of Insurance on Overall Survival in Acute Lymphoblastic Leukemia: A SEER Database Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	2
5	Association of insurance types and outcomes in acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2627-2635.	0.6	1
6	Effect of Age and Socioeconomic Factors in the Utilization of Chemotherapy in Acute Lymphoblastic Leukemia (ALL): A SEER Database Study of 16,196 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e907-e914.	0.2	3
7	Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E59-E63.	2.0	11
8	Development and validation of the Therapy Preference Scale to understand patients' systemic cancer treatment preferences. <i>Future Oncology</i> , 2021, 17, 37-44.	1.1	2
9	Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1949-1957.	0.6	9
10	Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6587-6587.	0.8	0
11	Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?. <i>Leukemia and Lymphoma</i> , 2020, 61, 7-17.	0.6	6
12	Effects of Obesity on Overall Survival of Adults With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e131-e136.	0.2	10
13	Treatment Strategies for Therapy-related Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 147-155.	0.2	10
14	Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 804-812.e8.	0.2	19
15	Do USMLE steps, and ITE score predict the American Board of Internal Medicine Certifying Exam results?. <i>BMC Medical Education</i> , 2020, 20, 79.	1.0	23
16	Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1702-1708.	0.6	9
17	Effects of Distance From Academic Cancer Center on Overall Survival of Acute Myeloid Leukemia: Retrospective Analysis of Treated Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e685-e690.	0.2	6
18	An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Advances in Hematology</i> , 2020, 2020, 1-10.	0.6	24

#	ARTICLE	IF	CITATIONS
19	Understanding therapy preferences of cancer patients with the use of therapy preference scale.. Journal of Clinical Oncology, 2020, 38, e24186-e24186.	0.8	1
20	Usefulness of Charlson comorbidity index (CCI) to predict early mortality and overall survival (OS) in acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, e19129-e19129.	0.8	0
21	Evaluation of high-dose methotrexate serum concentration requirement for discharge.. Journal of Clinical Oncology, 2020, 38, e19204-e19204.	0.8	0
22	Anatomical Variations in Circle of Willis in Patients Undergoing CT Cerebral Angiography in a Tertiary Hospital in Nepal: A Descriptive Cross-sectional Study. Journal of the Nepal Medical Association, 2020, 58, 1065-1068.	0.1	2
23	Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML). Blood, 2020, 136, 41-42.	0.6	1
24	Early Mortality and Overall Survival in Acute Promyelocytic Leukemia: Do Real-World Data Match Results of the Clinical Trials?. Blood, 2020, 136, 13-14.	0.6	0
25	Initial management of immune thrombocytopaenia in adults based on risk stratification. Postgraduate Medical Journal, 2019, 95, 558-562.	0.9	2
26	Effects of center type and socioeconomic factors on early mortality and overall survival of diffuse large B-cell lymphoma. Future Oncology, 2019, 15, 2113-2124.	1.1	7
27	Overutilisation of imaging studies for diagnosis of pulmonary embolism: are we following the guidelines?. Postgraduate Medical Journal, 2019, 95, 420-424.	0.9	22
28	Effectiveness of Sequential Compression Devices in Prevention of Venous Thromboembolism in Medically Ill Hospitalized Patients: A Retrospective Cohort Study. Turkish Journal of Haematology, 2019, 36, 193-198.	0.2	3
29	Immune-related adverse events in melanoma: A nationwide analysis 2016.. Journal of Clinical Oncology, 2019, 37, e18253-e18253.	0.8	0
30	Effects of obesity on overall survival (OS) of patients with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2019, 37, e18510-e18510.	0.8	0
31	Therapy preference scale: A novel questionnaire to understand patients's™ preferences of cancer treatment.. Journal of Clinical Oncology, 2019, 37, e23179-e23179.	0.8	1
32	Pemetrexed Induced Life-threatening Anaphylaxis. Cureus, 2019, 11, e5514.	0.2	1
33	Atypical chronic myeloid leukemia: a rare entity with management challenges. Future Oncology, 2018, 14, 177-185.	1.1	16
34	Spontaneous tumour lysis syndrome in small cell lung cancer: a rare phenomenon. BMJ Case Reports, 2018, 2018, bcr-2018-224512.	0.2	8
35	CAN WE Predict Risk Factors of Venous Thromboembolism Among Cancer Inpatients?. Blood, 2018, 132, 5871-5871.	0.6	1
36	Serendipitous Discovery of Factor VII Deficiency and the Ensuing Dilemma. MÃ dica, 2018, 13, 71-73.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Eculizumab in Transplant-Associated Thrombotic Microangiopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 175-180.	0.7	48
38	An Algorithmic Approach to Management of Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 511-517.	0.7	1
39	Chylothorax: A Review of Management Options. <i>Clinical Pulmonary Medicine</i> , 2017, 24, 66-68.	0.3	2
40	Central nervous system complications after allogeneic hematopoietic stem cell transplantation. <i>Future Oncology</i> , 2017, 13, 2297-2312.	1.1	13
41	Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 410-415.	0.7	47
42	Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?. <i>Bone Marrow Transplantation</i> , 2017, 52, 352-356.	1.3	25
43	Renal Cancer in Recipients of Kidney Transplant. <i>Rare Tumors</i> , 2017, 9, 9-13.	0.3	9
44	Use of Digital Technology to Optimize Functional Status in an Older Patient With Myelodysplastic Syndrome. <i>Journal of Oncology Practice</i> , 2017, 13, 141-142.	2.5	3
45	THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017019.	0.5	34
46	Cryptogenic Stroke. <i>New England Journal of Medicine</i> , 2016, 375, e26.	13.9	52
47	Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 12-20.	0.7	45
48	Mycophenolate Mofetil (MMF)-Induced Colitis. <i>Blood</i> , 2016, 128, 4795-4795.	0.6	7
49	Hospital Volume Does Not Influence in-Hospital Mortality of Autologous Hematopoietic Cell Transplant Among Multiple Myeloma Patients in the United States. <i>Blood</i> , 2016, 128, 392-392.	0.6	0
50	Heparin Reexposure in Patients With a History of Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 626-631.	0.7	19
51	Demographic and other characteristics of nodal non-Hodgkin's lymphoma managed in academic versus non-academic centers. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 223-227.	1.1	6
52	New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 13, 87-91.	0.4	8
53	Myxedema Coma with Reversible Cardiopulmonary Failure: a Rare Entity in 21 Century. <i>Mădica</i> , 2015, 10, 268-271.	0.4	0
54	Tuberous sclerosis complex with autosomal dominant polycystic kidney disease: a rare duo. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014207471-bcr2014207471.	0.2	11

#	ARTICLE	IF	CITATIONS
55	Exertional Chest Pain and Dyspnea From Hyperviscosity Syndrome Related to Marginal Zone Lymphoma. World Journal of Oncology, 2014, 5, 175-177.	0.6	0
56	Aortic dissection as a rare complication of percutaneous coronary intervention. BMJ Case Reports, 2014, 2014, bcr2014206414-bcr2014206414.	0.2	0